Sunitinib for the treatment of metastatic renal cell carcinoma.
about
Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumorsEvolving Therapies and FAK Inhibitors for the Treatment of CancerImmunotherapy for metastatic renal cell carcinoma.Crystal structure of ethyl 5''-fluoro-2'',3-dioxo-6',7',8',8a'-tetra-hydro-2'H,3H,5'H-di-spiro-[benzo[b]thio-phene-2,1'-indol-izine-3',3''-indoline]-2'-carboxyl-ate.Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis.Experience with sunitinib in the treatment of metastatic renal cell carcinoma5-Chloro-N-{4-oxo-2-[4-(trifluoro-meth-yl)phen-yl]-1,3-thia-zolidin-3-yl}-3-phenyl-1H-indole-2-carboxamideLaparoscopic excision of local recurrence of renal cell carcinoma.Rationale for the design of an oncology trial using a generic targeted therapy multi‑drug regimen for NSCLC patients without treatment options (Review)Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea.Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature.Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis.Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions.Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents.The green tea polyphenol EGCG potentiates the antiproliferative activity of sunitinib in human cancer cells.Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-Naïve Patient: A Comprehensive Review of the Literature.
P2860
Q26823873-6452BEF1-AE9F-4032-90E4-B214D86DE4D9Q28972291-F32D9913-AAE5-4960-808F-7CDF3F973E8FQ30234458-31339689-F6A1-45AF-94CA-05EA0407C28BQ35150934-80AF9E75-CC88-44AB-8E36-4F78569A8747Q35187896-4EF922D7-5AB4-4B3E-B199-4FCD9E87279CQ36231729-16B9131F-8FCD-47BA-AFC4-5934445D51C2Q36314404-3D1DDAFF-4B59-4943-B1D8-6F5DA5D13782Q36573512-9580C0AF-2C88-46F4-98BC-52049B77F488Q37260992-EE68F8E4-B13B-4D86-AA5F-84BCB08F2BB5Q37598818-74E63C63-53BE-459B-B110-947BF03FB8CEQ38169098-2CA2C5F1-57A3-470A-9F54-6D589D8EFD48Q38284400-49EEA22F-0BE5-4F86-8425-E420C0EEE1BCQ43557056-852BD438-4212-4311-8981-5890367827E2Q48261468-32614B79-990D-4D0D-B40F-75CD196D33E4Q50235806-EA638C71-9A92-44A6-86BF-05229C0A2700Q55332559-D98F2AB4-664E-4F27-BE35-B3EAA9518FAC
P2860
Sunitinib for the treatment of metastatic renal cell carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sunitinib for the treatment of metastatic renal cell carcinoma.
@en
Sunitinib for the treatment of metastatic renal cell carcinoma.
@nl
type
label
Sunitinib for the treatment of metastatic renal cell carcinoma.
@en
Sunitinib for the treatment of metastatic renal cell carcinoma.
@nl
prefLabel
Sunitinib for the treatment of metastatic renal cell carcinoma.
@en
Sunitinib for the treatment of metastatic renal cell carcinoma.
@nl
P2093
P1476
Sunitinib for the treatment of metastatic renal cell carcinoma
@en
P2093
Jasper Decoene
Peter Albers
Stéphane Oudard
P304
P356
10.1016/J.CTRV.2010.08.005
P577
2011-05-01T00:00:00Z